Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Arbutus Biopharma Corp shares valued at $804,850 were purchased by McElhaugh Michael J. on Apr 21 ’25. At $3.26 per share, McElhaugh Michael J. acquired 246,886 shares.
Also, McElhaugh Michael J. purchased 53,114 shares, netting a total of over 170,098 in proceeds.
Before that, Sofia Michael J. had added 250,000 shares to its account. In a trade valued at $875,000, the Officer bought Arbutus Biopharma Corp shares for $3.50 each.
As published in a research note from Jefferies on February 02, 2022, Arbutus Biopharma Corp [ABUS] has been rated up from a Hold to a Buy and the price target has been revised to $5. Analysts at Jefferies started covering the stock with ‘”a Hold”‘ outlook in a report released in late February. As of December 17, 2020, H.C. Wainwright has initiated its “Buy” rating for ABUS.
Analyzing ABUS Stock Performance
During the last five days, there has been a drop of approximately -8.59%. Over the course of the year, Arbutus Biopharma Corp shares have jumped approximately 0.92%. Shares of the company reached a 52-week high of $3.72 on 05/02/25 and a 52-week low of $2.70 on 04/09/25. A 50-day SMA is recorded $3.31, while a 200-day SMA reached $3.59.
Support And Resistance Levels for Arbutus Biopharma Corp (ABUS)
According to the 24-hour chart, there is a support level at 3.15, which, if violated, would cause prices to drop to 3.01. In the upper region, resistance lies at 3.40. The next price resistance is at 3.50. RSI (Relative Strength Index) is 48.30 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.07, which suggests the price will decrease in the coming days. Percent R is at 66.41%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
